$Moleculin Biotech (MBRX.US)$ NEWS Moleculin Announces U.S. ...
NEWS
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
The issuance of the U.S. Patent for Lipid-Based Delivery Technology for Annamycin provides composition protection until 2040, with the potential for extension, enhancing the Company's intellectual property portfolio.
Annamycin, the next-generation anthracycline developed by Moleculin, has demonstrated promising results in clinical studies, showing non-cardiotoxic properties and high response rates in AML patients, indicating potential for effective treatment.
The Company's commitment to advancing the development of Annamycin and its potential for treating various indications highlights a strong focus on innovation and addressing unmet medical needs in the field of oncology.
Annamycin, the next-generation anthracycline developed by Moleculin, has demonstrated promising results in clinical studies, showing non-cardiotoxic properties and high response rates in AML patients, indicating potential for effective treatment.
The Company's commitment to advancing the development of Annamycin and its potential for treating various indications highlights a strong focus on innovation and addressing unmet medical needs in the field of oncology.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
698Followers
75Following
4372Visitors
Follow